Story · Medicine & Biotech

Fracture rate and determinants of fractures and bone loss in women with postmenopausal osteoporosis discontinuing alendronate treatment: protocol for the Alendronate Discontinuation Study (ALEXIS) - a multicentre, randomised controlled trial

1 outlet · first reported by BMJ Open 15h ago

Coverage, in order

  1. 15h ago
    BMJ Open UK indie study randomized trialn=1400
    Fracture rate and determinants of fractures and bone loss in women with postmenopausal osteoporosis discontinuing alendronate treatment: protocol for the Alendronate Discontinuation Study (ALEXIS) - a multicentre, randomised controlled trial

    STRENGTHS AND LIMITATIONS OF THIS STUDY This nationwide, multicentre randomised controlled trial with 1400 participants will have sufficient statistical power to assess relative fracture risk when discontinuing alendronate treatment. This study is characterised by its pragmatic design, which…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.